What is Coming Next at the Innovative Medicines Initiative?

European Commission
Directorate-General for Research and Innovation
Directorate F – Health
Alain Vanvossel, MD
Why IMI?

• Decline in R&D industrial productivity despite steadily increasing R&D expenditures
  => research bottlenecks in the drug development process
• Loss of European competitiveness in the sector
• Europe is good at putting stakeholders together, based on the EU experience from the Framework Programmes
• Europe has the potential and capacity of innovation, based on a tissue of entrepreneurial universities and SMEs
• Common initiative EC – Pharma industry
• Faster and better drugs for the patient
IMI Objectives

- New pre-competitive research tools
- The IMI JU is a Public-Private Partnership
- New approach to support research in FP7 Health Theme
- Re-invigorate the drug development process
- Increase competitiveness EU pharma sector

Better and faster medicines for patients
What do we expect for IMI

- Address open innovation
- Address unmet Medical needs
- Guarantee uptake of new scientific and industrial precompetitive research tools
- Tool to reinvigorate drug development for the benefit of patients
- Consolidate research networks and PP collaboration
What is achieved

• 2 calls implemented:
  – 23 projects running in 2011 with ~190M€ from IMI JU and ~200 M€ from EFPIA companies

• 3rd call in the pipeline - 4th call in June 2011

• Update of scientific research agenda by this summer 2011

• Solid reflection on remaining calls engaged

• Interim evaluation of IMI JU finalised
Project from the 1st call (€8.2 M from IMI; €13.2 M EFPIA in-kind)
To overcome major bottlenecks in developing models and methods in drug
discovery for schizophrenia and depression
- Lack of accurate animal models
- Lack of tools and tests to provide early indication of efficacy
- Reliance on old clinical trial methodology

NEWMEDS project pools data of 23,401 anonymized schizophrenia patients from 67
trials on 11 compounds in over 25 countries

The single largest database of clinical trial data ever amassed in psychiatric research

For depression, bringing together
Data from public projects and 3 companies on the genetics and clinical response in 1,800 well characterised patients
Outlook

- **Innovation at the heart of the Europe 2020 strategy for growth and jobs: Innovation Union**

- **Commission green paper on a Common Strategic Framework for European research:**
  - Focus on world-beating science base, boosting competitiveness, tackling grand challenges such as health and ageing population
  - Making EU funding more attractive and easier to access; funding instruments covering the full innovation chain, including basic research, applied research, collaboration between academia and industry and firm-level innovation
  - Simpler and more consistent accounting procedures for use of funds

  Public Consultation open until 20 May:
  http://ec.europa.eu/research/consultations/csfri/consultation_en.htm

  Commission will make legislative proposal before end of 2011

  Part of the 2014-2020 multiannual financial framework
What about the future?

• Harvesting on the results from ongoing projects
• Define performance indicators and assess impact of IMI.
• Define « IdealHouse » for PPP. How does/will IMI fit in this?
• What about IMI.2? If any, what would it look like?